Long
Sinovac Biotech, Ltd.
No trades
No trades
Compare with Sinovac Biotech, Ltd.
−1.37 USD
−59.68 M USD
386.01 M USD
20.59 M
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
Company info
Sector
Industry
CEO
Wei Dong Yin
Website
Headquarters
Beijing
Founded
1993
IPO date
Nov 13, 2009
ISIN
AGP8696W1045
CUSIP
P8696W104
FIGI
BBG000D0D8P5
Identifiers
ISIN AGP8696W1045
Sinovac Biotech Ltd. is a holding company, which engages in the research, development, manufacture, and commercialization of vaccines that protect against human infectious diseases. Its product portfolio includes vaccines against enterovirus71, or EV71, hepatitis A and B, seasonal influenza, H5N1 pandemic influenza, H1N1 influenza, and mumps. The company was founded in 1993 and is headquartered in Beijing, China.
Summarizing what the indicators are suggesting.
Oscillators
Neutral
Oscillators
Neutral
Summary
Neutral
Summary
Neutral
Summary
Neutral
Moving Averages
Neutral
Moving Averages
Neutral
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently asked questions
The current price of SVA is 6.47 USD — it has decreased by −0.31% in the past 24 hours. Watch Sinovac Biotech, Ltd. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Sinovac Biotech, Ltd. stocks are traded under the ticker SVA.
Today Sinovac Biotech, Ltd. has the market capitalization of 464.94 M, it has increased by 0.93% over the last week.
Yes, you can track Sinovac Biotech, Ltd. financials in yearly and quarterly reports right on TradingView.
Sinovac Biotech, Ltd. is going to release the next earnings report on May 3, 2027. Keep track of upcoming events with our Earnings Calendar.
SVA net income for the last half-year is −60.24 M USD, while the previous report showed −38.01 M USD of net income which accounts for 0.00% change. Track more Sinovac Biotech, Ltd. financial stats to get the full picture.
As of Sep 27, 2026, the company has 2.6 K employees. See our rating of the largest employees — is Sinovac Biotech, Ltd. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Sinovac Biotech, Ltd. EBITDA is −117.10 M USD, and current EBITDA margin is −48.61%. See more stats in Sinovac Biotech, Ltd. financial statements.
Like other stocks, SVA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Sinovac Biotech, Ltd. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Sinovac Biotech, Ltd. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Sinovac Biotech, Ltd. stock shows the sell signal. See more of Sinovac Biotech, Ltd. technicals for a more comprehensive analysis.